surpass-2 tirzepatide vs semaglutide weight loss Efficacy of versus in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the Trial | Diabetologia Semaglutide vs Tirzepatide: Which GLP-1

Nerve: 300 to 500 mcg once or twice daily, subcutaneous, 8 to 12 weeks

(1) Bailes J, Soloviev M

Whole Foods Focus: Emphasize whole, unprocessed foods like fruits, vegetables, whole grains, and healthy fats

GIP medications target the glucose-dependent insulinotropic polypeptide (GIP) pathway, a hormone involved in glucose metabolism and appetite regulation

A higher proportion reached clinically meaningful weight-loss thresholds, with greater improvements in cardiometabolic markers

Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, has seen explosive uptake due to its efficacy in glycemic control, weight loss and cardiometabolic risk reduction, driving multibillion-dollar revenues for originator companies Novo Nordisk (maker of semaglutide products Ozempic and Wegovy) and Eli Lilly (the pharma giant behind the tirzepatide products Mounjaro and Zepbound)